A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation (VX17-445-105)
Details
- Therapeutic category
- Restore CFTR Function
- Trial status
- Closed to recruitment - in follow up Participating Centres
- Phase
- Phase III
Full title
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation- Trial Reference Number
- 109563
- Trial type
- Medication
- Recruitment target
- 460
- Last edited date
- 07/02/2020
- CF sponsor
- Vertex Pharmaceuticals Incorporated
- CF sponsor type
- Commercial
Who can take part?
- Top inclusion criteria
- Completed study drug treatment or scheduled visits in a parent study
- Age 12 Years and older
- Homozygous or heterozygous for F508del
- Top exclusion criteria
- History of drug intolerance in a parent study
- Current participation in an investigational drug trial (other than a parent study)